Prime Medicine
PRME· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +18.8% in FY2025
Allan Reine, M.D. is the CEO of Prime Medicine and was paid $3.9M in FY2025 (Dec).
Pay$100 in the stock at the end of FY24 → $119
Executives4
See all- 1Allan Reine, M.D.Chief Executive OfficerFY2025
- 2Keith GottesdienerFormer Chief Executive OfficerFY2025
- 3Ann Lee, Ph.D.FY2025
- 4Jeremy Duffield, M.D., Ph.D., FRCPFormer Chief Scientific OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allPrime Medicine paid its 4 named executives $9.0M in total in FY2025 (Dec). CEO Allan Reine, M.D. was paid $3.9M of that.
| Name | |||
|---|---|---|---|
| Allan Reine, M.D.Chief Executive Officer | Not disclosed | Not disclosed | |
| Keith GottesdienerFormer Chief Executive Officer | Not disclosed | Not disclosed | |
| Ann Lee, Ph.D. | Not disclosed | ||
| Jeremy Duffield, M.D., Ph.D., FRCPFormer Chief Scientific Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Prime Medicine. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board3
See all- Robert NelsenDirector · 5 yr on the boardIndependentCompensation—Paid as an executive
- Kaye FosterDirector · 4 yr on the boardIndependentCompensation (Chair)—Paid as an executive
- Michael A. KellyDirector · 4 yr on the boardIndependentAudit (Chair)—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 23, 2026 | FY2025 |
| Annual report | 10-K | Mar 3, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 22, 2025 | FY2024 |
| Annual report | 10-K | Feb 28, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 29, 2024 | FY2023 |
| Annual report | 10-K | Mar 1, 2024 | FY2023 |
